| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia |
|
Leukemia |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Rethinking clinical trial endpoints in myelodysplastic syndromes. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
